Shareholder Alert: Ademi LLP investigates whether Oyster Point Pharma, Inc. has obtained a Fair Price in its transaction with Viatris

Provided By PR Newswire

Last update: Nov 7, 2022

MILWAUKEE, Nov. 7, 2022 /PRNewswire/ -- Ademi LLP is investigating Oyster Point Pharma (NASDAQ: OYST) for possible breaches of fiduciary duty and other violations of law in its transaction with Viatris.